Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Roth

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
The Lancet. Rheumatology|January 27, 2024
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trialSaira Z Sheikh, Morton A Scheinberg, James Cheng-Chung Wei, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
The Lancet. Rheumatology|January 27, 2024
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trialSaira Z Sheikh, Morton A Scheinberg, James Cheng-Chung Wei, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.
Pageof 6